Enhancing Oxygen,
Fueling Life
Targeting Treatments for Hypoxia
Learn more
Diffusion Pharmaceuticals

Improving Oxygen Availability
to Vital Organs

A Treatment for Life-Threatening Conditions Related to Hypoxia

Novel Mechanism of Action

Lead drug trans sodium crocetinate (TSC) enhances the availability of oxygen by improving diffusion through the blood.

Selective for Hypoxic Tissue

TSC’s mechanism of action enhances oxygen availability to hypoxic tissue without oversupplying normoxic tissue.

Attractive Safety Profile

TSC has been safe and well tolerated in completed preclinical and clinical studies.

OUR PIPELINE

Potential treatment
of COVID-19

Diffusion Pharmaceuticals is actively evaluating trans sodium crocetinate (TSC)’s potential to improve the availability of oxygen in patients with COVID-19, building upon data from prior clinical studies in peripheral artery disease and glioblastoma multiform (GBM) brain cancer.

Learn more

Scientific Publications

Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator. Brain Research. 2010; 1309:136-145.

Protection against focal ischemic injury to the brain by trans-sodium crocetinate. J Neurosurg. 2010; 113:802-809.

Metabolic reflow as a therapy for ischemic brain injury. H. Feng et al. (eds.), Early Brain Injury or Cerebral Vasospasm, Acta Neurochirurgica Supplementum, Vol. 110/2, DOI 10.1007/978-3-7091-0356-2_16, # Springer-Verlag/Wien 2011.

Trans-sodium crocetinate improves outcomes in rodent models of occlusive and hemorrhagic stroke. Brain Research. 2014; 1583:245-254.

Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. J Neurosurf. 2016: JNS515-2693

Trans sodium crocetinate: functional neuroimaging studies in a hypoxic brain tumor: Laboratory investigation. J Neurosurg. 2011; 115:749-753.

Effect of trans sodium crocetinate on brain tumor oxygenation: Laboratory investigation. J Neurosurg. 2009; 111:226–229.

Trans sodium crocetinate sensitizes glioblastoma multiforme tumors to radiation. J Neurosurg. 2008; 108:972-978.

Trans-sodium crocetinate for treating hypoxia/ischemia. Expert Opinion on Investigational Drugs. 2008; 17:917-24.

News

The latest news, press releases, and more.

Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock

 Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., February 18, 2021 — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock

 Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., February 17, 2021 — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients

 Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Feb. 16, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference

 Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE)

Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates

 Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Nov. 12, 2020 (GLOBE NEWSWIRE)

Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer

 Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va. (October 19, 2020) – Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary

 Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE)

Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference

 Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE)

Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial

 Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 10, 2020 (GLOBE NEWSWIRE)

Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer

 Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE)

Back to top